 |
PDBsum entry 6b1e
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
6b1e
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase/hydrolase inhibitor
|
 |
|
Title:
|
 |
The structure of dpp4 in complex with vildagliptin
|
|
Structure:
|
 |
Dipeptidyl peptidase 4. Chain: a, b. Synonym: adabp,adenosine deaminase complexing protein 2,adcp-2, dipeptidyl peptidase iv,dpp iv,t-cell activation antigen cd26,tp103. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: dpp4, adcp2, cd26. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108
|
|
Resolution:
|
 |
|
1.77Å
|
R-factor:
|
0.162
|
R-free:
|
0.186
|
|
|
Authors:
|
 |
G.Scapin
|
|
Key ref:
|
 |
J.P.Berger
et al.
(2018).
A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice.
Endocrinol Diabetes Metab,
1,
e00002.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
18-Sep-17
|
Release date:
|
27-Sep-17
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P27487
(DPP4_HUMAN) -
Dipeptidyl peptidase 4 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
766 a.a.
728 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
|
*
PDB and UniProt seqs differ
at 1 residue position (black
cross)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.4.14.5
- dipeptidyl-peptidase Iv.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Release of an N-terminal dipeptide, Xaa-Xbb-|-Xcc, from a polypeptide, preferentially when Xbb is Pro, provided Xcc is neither Pro nor hydroxyproline.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Endocrinol Diabetes Metab
1:e00002
(2018)
|
|
PubMed id:
|
|
|
|
|
| |
|
A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice.
|
|
J.P.Berger,
R.SinhaRoy,
A.Pocai,
T.M.Kelly,
G.Scapin,
Y.D.Gao,
K.A.D.Pryor,
J.K.Wu,
G.J.Eiermann,
S.S.Xu,
X.Zhang,
D.A.Tatosian,
A.E.Weber,
N.A.Thornberry,
R.D.Carr.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |